Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial

The therapeutic window of opportunity in rheumatoid arthritis: does it ever close?

(2015) Karim Raza et al.   ANNALS OF THE RHEUMATIC DISEASES

Combination conventional DMARDs compared to biologicals

(2015) Manpreet K. Sethi et al.   CURRENT OPINION IN RHEUMATOLOGY

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial

(2015) D. L. Scott et al.   BMJ-British Medical Journal

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial

(2015) D. L. Scott et al.   BMJ-British Medical Journal

Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial

(2014) Jonas K Eriksson et al.   ANNALS OF THE RHEUMATIC DISEASES

What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review

(2013) J A B van Nies et al.   ANNALS OF THE RHEUMATIC DISEASES

Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial

(2013) Vappu Rantalaiho et al.   ANNALS OF THE RHEUMATIC DISEASES

Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?

(2013) Jonas K Eriksson et al.   ANNALS OF THE RHEUMATIC DISEASES

Validation of the Methotrexate-First Strategy in Patients With Early, Poor-Prognosis Rheumatoid Arthritis: Results From a Two-Year Randomized, Double-Blind Trial

(2013) James R. O'Dell et al.   ARTHRITIS AND RHEUMATISM

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure

(2013) James R. O'Dell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis

(2013) Jonas K. Eriksson et al.   JAMA Internal Medicine

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial

(2012) Johan A Karlsson et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

(2012) Larry W. Moreland et al.   ARTHRITIS AND RHEUMATISM

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

(2012) Ronald F van Vollenhoven et al.   LANCET

Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice

(2011) M. Neovius et al.   ANNALS OF THE RHEUMATIC DISEASES

In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial

(2011) Hamed Rezaei et al.   ANNALS OF THE RHEUMATIC DISEASES

How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop?

(2011) M. Neovius et al.   ANNALS OF THE RHEUMATIC DISEASES

The burden of illness of rheumatoid arthritis

(2011) Annelies Boonen et al.   CLINICAL RHEUMATOLOGY

Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955-2007

(2010) Elena Myasoedova et al.   ARTHRITIS AND RHEUMATISM

Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: Work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study

(2010) Ronald F. van Vollenhoven et al.   ARTHRITIS CARE & RESEARCH

Societal cost of rheumatoid arthritis patients in the US

(2009) Howard Birnbaum et al.   CURRENT MEDICAL RESEARCH AND OPINION

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

(2009) RF van Vollenhoven et al.   LANCET

The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study

(2009) A. Anis et al.   RHEUMATOLOGY

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis

(2008) Victoria Bejarano et al.   ARTHRITIS AND RHEUMATISM

Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US

(2008) Saralynn Allaire et al.   ARTHRITIS AND RHEUMATISM